Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, June 30, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN)investors that the law firm has initiated an investigation on behalf of investors that lost money on their Regeneron stock. Regeneron investors are encouraged to contact the firm to discuss their legal rights.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The focal point of the investigation revolves around the Company's potential issuance of inaccurate or deceptive statements, as well as its alleged failure to divulge crucial information of significance to investors. On June 27, 2023, Regeneron received a response letter from the FDA, wherein the agency declined to grant approval for the Company's application seeking an 8mg dosage of aflibercept, marketed as Eylea within the United States. Regeneron asserts that the denial is attributable to an ongoing assessment of findings pertaining to a third-party filler. Subsequently, upon the dissemination of this news, Regeneron's shares experienced a decline surpassing 9% on the very same day.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
